On September 8, 2026, Intellia Therapeutics announced that the U.S. Food and Drug Administration accepted its Biologics License Application for lonvoguran ziclumeran (lonvo-z) to treat hereditary angioedema. The FDA granted Priority Review status with a PDUFA target action date of March 10, 2027, and indicated no advisory committee is currently planned. Lonvo-z is an in vivo CRISPR-based therapy designed as a one-time treatment for the rare genetic disease. Clinical data from the Phase 3 HAELO trial showed an 87% reduction in mean monthly attacks compared to placebo, with 62% of patients achieving complete attack freedom during the evaluation period. Intellia Therapeutics is a biopharmaceutical company focused on developing curative treatments using CRISPR gene editing technology.

Intellia Therapeutics entered into a $400 million senior secured credit facility with OrbiMed on September 4, 2026. The company drew $75 million upfront at closing. Additional tranches totaling up to $325 million are available based on milestones: $75 million upon FDA approval of the BLA for lonvoguran ziclumeran (lonvo-z), three $40 million draws upon achieving specific revenue targets for lonvo-z, and a $30 million draw upon reaching an equity fundraising target. The facility matures in September 2031 with interest at SOFR plus 6.15%. Intellia Therapeutics is a biopharmaceutical company focused on developing CRISPR-based gene editing therapies.

Intellia Therapeutics reported second quarter 2026 financial results, including a net loss of $106.6 million and ending cash reserves of approximately $628 million. The company announced positive Phase 3 HAELO clinical data for lonvo-z in hereditary angioedema, showing an 87% reduction in attacks versus placebo, and expects FDA acceptance of the BLA in the second half of 2026 with a U.S. launch planned for early 2027. Additionally, enrollment was reinitiated in nex-z Phase 3 trials for ATTR amyloidosis, with MAGNITUDE-2 expected to complete by late 2026. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on developing CRISPR gene editing therapies.

Intellia Therapeutics reported positive Phase 3 HAELO trial results for lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema, showing an 87% reduction in mean monthly attacks compared to placebo. The trial met its primary endpoint and secondary endpoints, including a 62% attack-free rate for patients in the lonvo-z arm. The company initiated a rolling biologics license application with the FDA in April and anticipates a U.S. launch in the first half of 2027. Intellia Therapeutics is a biotechnology company developing CRISPR/Cas9 gene-editing therapies.